In contrast to Type 1 RTS patients, who have no elevation in risk of osteosarcoma, Type 2 RTS patients with biallelic RECQL4 pathogenic variants have a significantly elevated lifetime risk of osteosarcoma. This evidence concerns the gene RECQL4 and osteosarcoma.